Genitourinary Cancers

The observed narrowing of racial disparities in prostate cancer outcome since the advent of PSA screening is not as large as previously believed.

The approval of the oral androgen-receptor inhibitor apalutamide (Erleada) is the first to be based on metastasis-free survival.

Pazopanib was not associated with prolonged progression-free survival compared with temsirolimus among patients with advanced clear-cell renal cell carcinoma, but a subgroup analysis of intermediate-risk patients offered some reason for optimism.

Adjuvant platinum-based chemotherapy is associated with delayed metastasis among patients diagnosed with upper-tract urothelial carcinoma, according to findings from the phase III POUT trial.

Adjuvant therapy with sunitinib after nephrectomy was associated with increased mortality among older women with renal cell carcinoma, according to a subgroup analysis of data from the ASSURE trial.

Combining axitinib and pembrolizumab is “safe and tolerable” among patients with previously untreated advanced renal cell carcinoma, with 73% of patients responding, according to findings from an open-label, phase Ib trial.

Fewer patients diagnosed with testicular cancer were uninsured, and fewer were diagnosed with late-stage disease, following the Affordable Care Act’s Medicaid enrollment expansion.

Researchers reported promising safety data from an ongoing phase Ib/II clinical trial for SM-88, an investigational combination therapy that might one day offer an alternative to androgen deprivation therapy for men with recurrent, nonmetastatic prostate cancer.

Long-term follow-up showed that atezolizumab remained well tolerated over more than 3 years, with durable clinical benefit in metastatic urothelial carcinoma.

Enzalutamide resulted in a 71% reduction in metastatic disease risk among men with castration-resistant prostate cancer and rapid prostate-specific antigen doubling time, according to the first interim analysis of data from the phase III PROSPER trial. 

Researchers are developing a prognostic hypoxia gene signature for patients with localized prostate cancer that could predict biochemical failure and metastasis.

The US Food and Drug Administration has approved abiraterone acetate (Zytiga) tablets in combination with prednisone for the treatment of metastatic prostate cancer patients with high-risk, castration-sensitive disease.

Metastatic RCC patients treated with cabozantinib had similar quality-of-life outcomes as those treated with everolimus, but had a longer time to deterioration.

A newly developed clinical model can predict overall survival for patients diagnosed with advanced bladder cancer who are treated with atezolizumab.

Adding docetaxel chemotherapy to frontline hormone therapy improves quality of life and may reduce the need for subsequent treatment, according to an analysis from the STAMPEDE trial.

Adding atezolizumab and bevacizumab to standard care was tolerable and slowed tumor growth in patients with previously untreated clear-cell or sarcomatoid-histology metastatic renal cell carcinoma when compared to sunitinib, according to findings from a phase III study.

Apalutamide was well-tolerated and associated with delayed metastasis in men with high-risk castration-resistant prostate cancer that has become refractory to conventional hormone therapy, according to an early interim analysis of the phase III SPARTAN clinical trial.

Adjuvant radiotherapy after prostatectomy resulted in lower rates of biochemical recurrence, distant metastases, and death compared with surveillance followed by early-salvage radiotherapy in patients with high-risk prostate cancer, according to a new study.

Reduced expression of PBRM1 and VHL was correlated with increased tumor aggressiveness in clear cell renal cell carcinoma, according to the results of a recent study. 

The FDA has expanded the label for cabozantinib (Cabometyx) to include first-line treatment of advanced renal cell carcinoma regardless of treatment status. Cabozantinib was initially approved in patients who had previously received anti-angiogenic therapy.

Educational strategies including pamphlets and recommendations from family physicians and support from a specialist can improve bone care in men with prostate cancer undergoing androgen deprivation therapy.

A study found familial clustering of urothelial cancers, with increased risk of bladder cancer and others, in first- and second-degree relatives of these patients.

The immune checkpoint inhibitor avelumab showed promising antitumor activity and a manageable toxicity profile in patients with platinum-refractory metastatic urothelial carcinoma, according to a new analysis.

In this article, we discuss the requirements for development and validation of urine markers and the factors that hamper their clinical implementation. We also review current surveillance guidelines for NMIBC and provide an overview of approved urine markers for the detection and surveillance of NMIBC.

Researchers have discovered that testicular cancer’s responsiveness to conventional chemotherapy is likely determined during prenatal development.

Researchers found that combining palonosetron, aprepitant, and dexamethasone represents an effective and well-tolerated treatment to prevent CINV in testicular cancer patients receiving cisplatin.

A post-hoc analysis found that brain metastases are more frequent in patients with advanced germ cell tumors who have received dose-dense chemotherapy compared with those administered the BEP regimen.

Treatment with crizotinib resulted in objective responses in patients with advanced papillary renal cell carcinoma type 1 with MET mutations or amplification.

In a small phase II study of 12 men with nonseminoma germ cell tumors refractory to cisplatin, pembrolizumab did not demonstrate clinical activity.

Researchers analyzed a large population-based sample of men from Sweden and discovered an association between heavy cannabis use and testicular cancer incidence.